372 related articles for article (PubMed ID: 26724200)
1. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
4. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
[TBL] [Abstract][Full Text] [Related]
5. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
[TBL] [Abstract][Full Text] [Related]
6. Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus.
Zhang Z; Zhang J; Zhang J; Li Q; Miao P; Liu J; Li S; Huang J; Liao M; Fan H
Vet Microbiol; 2017 May; 203():143-148. PubMed ID: 28619136
[TBL] [Abstract][Full Text] [Related]
7. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
8. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
[TBL] [Abstract][Full Text] [Related]
9. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
10. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
11. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
12. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
Yang WT; Yang GL; Wang Q; Huang HB; Jiang YL; Shi CW; Wang JZ; Huang KY; Jin YB; Wang CF
Antiviral Res; 2017 Feb; 138():9-21. PubMed ID: 27908830
[TBL] [Abstract][Full Text] [Related]
13. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
[TBL] [Abstract][Full Text] [Related]
14. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
15. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
Prabakaran M; Kolpe AB; He F; Kwang J
Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
[TBL] [Abstract][Full Text] [Related]
17. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.
Calzas C; Mao M; Turpaud M; Viboud Q; Mettier J; Figueroa T; Bessière P; Mangin A; Sedano L; Hervé PL; Volmer R; Ducatez MF; Bourgault S; Archambault D; Le Goffic R; Chevalier C
Front Immunol; 2021; 12():772550. PubMed ID: 34868036
[TBL] [Abstract][Full Text] [Related]
19. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
20. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
Tang XC; Lu HR; Ross TM
Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
